Thelansis

Advanced Systemic Mastocytosis (AdvSM) Market Outlook Thelansis’s “Advanced Systemic Mastocytosis (AdvSM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Systemic Mastocytosis (AdvSM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have th...

  Advanced Systemic Mastocytosis (AdvSM) Market Outlook Thelansis’s “Advanced Systemic Mastocytosis (AdvSM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Systemic Mastocytosis (AdvSM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Advanced Systemic Mastocytosis (AdvSM) Overview Systemic mastocytosis is a diverse disorder marked by the accumulation of malignant mast cells in the bone marrow and various organs. The precise cause is not fully understood, although an activating mutation of the KIT gene, typically D816V, is evident in mast cells and occasionally in non-mast cell hematopoietic lineages. In advanced system...

  Systemic mastocytosis is a diverse disorder marked by the accumulation of malignant mast cells in the bone marrow and various organs. The precise cause is not fully understood, although an activating mutation of the KIT gene, typically D816V, is evident in mast cells and occasionally in non-mast cell hematopoietic lineages. In advanced systemic mastocytosis (AdvSM), additional mutations in genes like TET2, SRSF2, ASXL1, RUNX1, JAK2, N/KRAS, CBL, and less frequently, EZH2, IDH2, ETV6, U2AF, or SF3B1, contribute to disease aggressiveness, especially in multi-mutated cases. Over 80% of systemic mastocytosis patients exhibit KIT mutations, most commonly KIT D816V. While many experience an indolent disease, a subset faces aggressive variants collectively termed "advanced systemic mastocytosis," including aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. Advanced SM is a rare myeloid neoplasm characterized b...